Bavarian Nordic said on Tuesday that its MVA-BN Ebola vaccine regimen has entered the first phase of clinical trials.
The vaccine utilizes MVA-BN Filo and AdVac technology that has been developed by Crucell Holland B.V., a subsidiary of Johnson & Johnson. Recruitment and enrollment is currently in the completion process and early volunteers have already received initial dosages of the compound.
The trials are being led by the Oxford Vaccines Group, which will determine and evaluate the safety and human toleration to this regimen. The initial dose is to prepare the immune system; then a second dose is given that is supposed to boost the immune system's response. The study will ultimately enroll 72 volunteers to test the validity of this vaccine.
Trials will also be opening in the U.S. later this month, followed by trials in Africa. If results are positive, the compound will enter the next phases in the process.
“This first in-human trial of this Ebola vaccine regimen is a testament of the accelerated efforts by Bavarian Nordic, Johnson & Johnson, the public health authorities and other key stakeholders to make the vaccines broadly available to protect families and front line health care professionals," Bavarian Nordic President and CEO Paul Chaplin said.